Screening
NSCLC, PD
EVENTS, DISEASE, ADVERSE EVENT, NSCLC
Totally 317 NSCLC patients were screened, and 264 underwent randomization, including 131 and 133 in the envonalkib and crizotinib groups, respectively, both in the intent-to-treat (ITT) population and the safety set (SS). As of October 14, 2021, 135 PFS events were observed, and an interim analysis was performed. Considering the immature PFS data, follow-up for PFS was extended to August 31, 2022, when 81 and 105 participants had withdrawn from the study, while 50 and 28 were still on treatment in the envonalkib and crizotinib groups, respectively (Fig. Study flowchart. PD progressive disease, AE adverse event, ITT intent-to-treat, SS safety set